Skip to main content
Top
Published in: Cancer Cell International 1/2015

Open Access 01-12-2015 | Retraction Note

Retraction Note: Hypericin-mediated photodynamic therapy induces apoptosis of myoloma SP2/0 cells depended on caspase activity in vitro

Authors: Junping Zhang, Linxiang Shao, Chunlin Wu, Hongfei Lu, Ruian Xu

Published in: Cancer Cell International | Issue 1/2015

Login to get access

Excerpt

The Publisher and Editor regretfully retract this article [1] because the peer-review process was inappropriately influenced and compromised. As a result, the scientific integrity of the article cannot be guaranteed. A systematic and detailed investigation suggests that a third party was involved in supplying fabricated details of potential peer reviewers for a large number of manuscripts submitted to different journals. In accordance with recommendations from [COPE] we have retracted all affected published articles, including this one. It was not possible to determine beyond doubt that the authors of this particular article were aware of any third party attempts to manipulate peer review of their manuscript. …
Literature
1.
go back to reference Zhang J, Shao L, Wu C, Lu H, Xu R. Hypericin-mediated photodynamic therapy induces apoptosis of myoloma SP2/0 cells depended on caspase activity in vitro. Cancer Cell Int. 2014;14:136.CrossRef Zhang J, Shao L, Wu C, Lu H, Xu R. Hypericin-mediated photodynamic therapy induces apoptosis of myoloma SP2/0 cells depended on caspase activity in vitro. Cancer Cell Int. 2014;14:136.CrossRef
Metadata
Title
Retraction Note: Hypericin-mediated photodynamic therapy induces apoptosis of myoloma SP2/0 cells depended on caspase activity in vitro
Authors
Junping Zhang
Linxiang Shao
Chunlin Wu
Hongfei Lu
Ruian Xu
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2015
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-015-0199-8

Other articles of this Issue 1/2015

Cancer Cell International 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine